Related Experiment Video
Updated: Jun 18, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
[Blood concentration monitoring during high-dose methotrexate treatment]
Li Jiao1, Dao-Bin Zhou, Shu-Jie Wang
1Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
Objective:
To explore the clinical value of blood concentration monitoring during high-dose methotrexate (MTX) treatment.
Methods:
High-dose MTX (1.5-9.0 g) was infused to 105 patients with acute lymphoblastic leukemia or lymphoma, and then the blood MTX concentration was measured by fluorescence polarization immune assay (FPIA) 44 hours after the start of administration. The procedure was repeated every 6-12 hours until the concentration was less than 0.1 micromol/L.
Results:
Forty-four hours after the start of administration, the blood MTX concentration (C(MTX/44h)) was > or = 5 micromol/L in 6 patients (2.8%) and was between 1 and 5 micromol/L in 23 patients (10.6%). C(MTX/44h) > or = 1 micromol/L was more common in patients received 5.0 g MTX. No severe adverse event was observed in all patients.
Conclusions:
Blood MTX concentration is different after high-dose MTX treatment due to individual metabolic differences, and therefore it is clinically important to monitor blood concentration of MTX. Elimination delay is more common in patients receive 5.0 g MTX. Application of high-dose MTX therapy under the monitoring of blood MTX concentration is safe and feasible.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Therapeutic Drug Monitoring: Drug Analysis Methods
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Concentrations: Measurements
Plasma —...
Therapeutic Drug Monitoring: Overview and Classification
